137 related articles for article (PubMed ID: 21639)
21. Biliary excretion of diphenylhydantoin in the rat. Time-course studies.
Inaba T; Umeda T
Drug Metab Dispos; 1975; 3(2):69-73. PubMed ID: 236160
[TBL] [Abstract][Full Text] [Related]
22. Identification of 5-meta-hydroxyphenyl-5-phenylhydantoin as a metabolite of diphenylhydantoin.
Atkinson AJ; MacGee J; Strong J; Garteiz D; Gaffney TE
Biochem Pharmacol; 1970 Aug; 19(8):2483-91. PubMed ID: 5520606
[No Abstract] [Full Text] [Related]
23. The effect of pregnancy on the biliary excretion of [14C]phenytoin in the rat.
Vore M; Soliven E; Blunden M
J Pharmacol Exp Ther; 1979 Feb; 208(2):257-62. PubMed ID: 762658
[TBL] [Abstract][Full Text] [Related]
24. Oxygen-18 incorporation studies of the metabolism of phenytoin to the catechol.
Billings RE; Fischer LJ
Drug Metab Dispos; 1985; 13(3):312-7. PubMed ID: 2861989
[TBL] [Abstract][Full Text] [Related]
25. Two-dimensional high-performance liquid chromatographic method to assay p-hydroxyphenylphenylhydantoin enantiomers in biological fluids and stereoselectivity of enzyme induction in phenytoin metabolism.
Hsieh CY; Huang JD
J Chromatogr; 1992 Mar; 575(1):109-15. PubMed ID: 1517287
[TBL] [Abstract][Full Text] [Related]
26. In vivo distribution of carbon-11 phenytoin and its major metabolite, and their use in scintigraphic imaging.
Stavchansky SA; Tilbury RS; McDonald JM; Ting CT; Kostenbauder HB
J Nucl Med; 1978 Aug; 19(8):936-41. PubMed ID: 98619
[TBL] [Abstract][Full Text] [Related]
27. Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation.
Cuttle L; Munns AJ; Hogg NA; Scott JR; Hooper WD; Dickinson RG; Gillam EM
Drug Metab Dispos; 2000 Aug; 28(8):945-50. PubMed ID: 10901705
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous determination of plasma phenytoin and its primary hydroxylated metabolites in carbon tetrachloride-intoxicated rats by high-performance liquid chromatography.
Tanaka E; Sakamoto N; Inubushi M; Misawa S
J Chromatogr B Biomed Appl; 1995 Nov; 673(1):147-51. PubMed ID: 8925069
[TBL] [Abstract][Full Text] [Related]
29. An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin.
Riley RJ; Maggs JL; Lambert C; Kitteringham NR; Park BK
Br J Clin Pharmacol; 1988 Nov; 26(5):577-88. PubMed ID: 3207562
[TBL] [Abstract][Full Text] [Related]
30. [Chiral separation of racemic 5-(p-hydroxyphenyl)-5-phenylhydantoin by RP-HPLC using eluents containing beta-cyclodextrin].
Yao T; Zeng S; Ding H
Se Pu; 1997 Jul; 15(4):316-8. PubMed ID: 15739464
[TBL] [Abstract][Full Text] [Related]
31. [N-Hydroxylation of p-phenetidine in vivo and by isolated microsomes from liver and kidney: stimulation by phenobarbital pretreatment].
Uehleke H
Naunyn Schmiedebergs Arch Pharmakol; 1969; 264(4):434-61. PubMed ID: 4390525
[No Abstract] [Full Text] [Related]
32. Determination of 5-(3,4-Dihydroxy-1,5-cyclohexadien-1-yl)-5-phenylhydantoin (Dihydrodiol) and quantitative studies of phenytoin metabolism in man.
Maguire JH; Kraus BL; Butler TC; Dudley KH
Ther Drug Monit; 1979; 1(3):359-70. PubMed ID: 555579
[TBL] [Abstract][Full Text] [Related]
33. Influence of pregnancy and folic acid on phenytoin metabolism by rat liver microsomes.
Blake DA; Collins JM; Miyasaki BC; Cohen F
Drug Metab Dispos; 1978; 6(3):246-50. PubMed ID: 26544
[TBL] [Abstract][Full Text] [Related]
34. A comparison of diphenylhydantoin metabolism in different tissues using high performance liquid chromatography.
MacKinney AA; Shinnick FL; Gorder C
Res Commun Chem Pathol Pharmacol; 1982 Jun; 36(3):395-411. PubMed ID: 7122986
[TBL] [Abstract][Full Text] [Related]
35. Biotransformation of a novel antimitotic agent, I-387, by mouse, rat, dog, monkey, and human liver microsomes and in vivo pharmacokinetics in mice.
Ahn S; Kearbey JD; Li CM; Duke CB; Miller DD; Dalton JT
Drug Metab Dispos; 2011 Apr; 39(4):636-43. PubMed ID: 21233217
[TBL] [Abstract][Full Text] [Related]
36. UDP-glucuronosyltransferase-mediated protection against in vitro DNA oxidation and micronucleus formation initiated by phenytoin and its embryotoxic metabolite 5-(p-hydroxyphenyl)-5-phenylhydantoin.
Kim PM; Winn LM; Parman T; Wells PG
J Pharmacol Exp Ther; 1997 Jan; 280(1):200-9. PubMed ID: 8996197
[TBL] [Abstract][Full Text] [Related]
37. The elimination of phenytoin in man.
Eadie MJ; Tyrer JH; Bochner F; Hooper WD
Clin Exp Pharmacol Physiol; 1976; 3(3):217-24. PubMed ID: 975617
[TBL] [Abstract][Full Text] [Related]
38. Conversion of phenytoin to reactive metabolites in rat liver microsomes.
Billings RE; Milton SG
Adv Exp Med Biol; 1986; 197():931-9. PubMed ID: 3020938
[No Abstract] [Full Text] [Related]
39. 1-Acetyl-3-acetoxy-5'5-diphenylhydantoin has colchicine-like activity.
MacKinney AA; Vyas R; Mueller C
Res Commun Chem Pathol Pharmacol; 1984 May; 44(2):251-64. PubMed ID: 6739954
[TBL] [Abstract][Full Text] [Related]
40. Use of Frog Embryo Teratogenesis Assay-Xenopus and an exogenous metabolic activation system to evaluate the developmental toxicity of diphenylhydantoin.
Fort DJ; Bantle JA
Fundam Appl Toxicol; 1990 May; 14(4):720-33. PubMed ID: 2361573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
